TY  - JOUR
AU  - Dorman, Klara
AU  - Breitenwieser, Kilian
AU  - Fischer, Laura
AU  - Zhang, Danmei
AU  - Probst, Victoria
AU  - Weiss, Lena
AU  - Heinrich, Kathrin
AU  - Kunz, Wolfgang G
AU  - Holch, Julian W
AU  - Gießen-Jung, Clemens
AU  - Haas, Michael
AU  - Boeck, Stefan
AU  - von Bergwelt-Baildon, Michael
AU  - Landfarth, Timotheus
AU  - Hornung, Roman
AU  - Casuscelli, Jozefina
AU  - Berger-Thürmel, Karin
AU  - Heinemann, Volker
AU  - Westphalen, C. Benedikt
AU  - Reischer, Anna
TI  - Real-world analysis of immune checkpoint inhibitor efficacy and response predictors in patients treated at the CCCMunichLMU outpatient clinic.
JO  - Scientific reports
VL  - 15
IS  - 1
SN  - 2045-2322
CY  - [London]
PB  - Springer Nature
M1  - DKFZ-2025-02876
SP  - 43269
PY  - 2025
AB  - Prediction of response to checkpoint inhibition (ICI) and immune related adverse events (irAEs) remain a challenge in the immunotherapy of solid tumors. To better understand the real-world clinical courses under ICI and identify possible predictive markers for response and irAEs, we retrospectively collected and analysed data from our interdisciplinary CCCMunichLMU outpatient clinic. We analysed the clinical course, standard laboratory parameters and staging results of 342 patients who received ICI therapy in the interdisciplinary outpatient clinic of the CCCMunichLMU between January 2015 and November 2020. Initial response to ICI was defined as complete response, partial response, stable disease or mixed response with treatment continuation in the second radiologic staging after start of therapy. Median age of the included patients was 67 years (25-89). More male patients received ICI on our outpatient ward than female patients (67.8
KW  - Humans
KW  - Male
KW  - Female
KW  - Immune Checkpoint Inhibitors: therapeutic use
KW  - Immune Checkpoint Inhibitors: adverse effects
KW  - Aged
KW  - Middle Aged
KW  - Aged, 80 and over
KW  - Adult
KW  - Retrospective Studies
KW  - Neoplasms: drug therapy
KW  - Neoplasms: immunology
KW  - Treatment Outcome
KW  - Ambulatory Care Facilities
KW  - Adverse events (Other)
KW  - Autoimmune disorders (Other)
KW  - Immune checkpoint inhibitors (Other)
KW  - Immunotherapy (Other)
KW  - Response predictors (Other)
KW  - Solid tumors (Other)
KW  - Immune Checkpoint Inhibitors (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:41361351
C2  - pmc:PMC12686437
DO  - DOI:10.1038/s41598-025-30220-0
UR  - https://inrepo02.dkfz.de/record/306901
ER  -